Multiparametric MRI detects more local recurrences after prostatectomy than prostate-specific membrane antigen PET-CT, with the two showing only moderate agreement.
Quibim’s QP-Prostate® CAD, Including Lesion Detection and Diagnosis Capability, Cleared by FDA Quibim’s flagship solution, which uses biopsy data for training, has received 510 (k) clearance for use ...
November is Men’s Health Awareness Month, a time to spotlight the latest medical breakthroughs that may transform how we detect and treat cancer– especially prostate and skin cancer, which are among ...
Prostate and skin cancers are among the most common cancers affecting men. In Advanced Prostate Cancer, lifelong treatment modalities are making a difference, challenges remain for patients with ...
NEW YORK, Nov. 25, 2025 /PRNewswire/ -- Nucs AI, the leader in AI-based radiology solutions, today announced the launch of TrackPSMA, a breakthrough tool that gives physicians a faster, quantitative ...
OMAHA, Neb., Nov. 18, 2025 /PRNewswire/ -- Bot Image, Inc., a leader in AI-powered diagnostic imaging, today announced that its flagship software, ProstatID (R), has achieved UKCA certification under ...
Our study found that PZ biopsies offer no additional benefit for TZ lesion tumors, and increasing the number of cores in the TZ region can compensate for the current limitations of TZ biopsies. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback